电针对帕金森病大鼠室管膜下区细胞增殖和胶质原纤维酸性蛋白表达的影响

摘要

目的:观察电针对帕金森病(PD)大鼠室管膜下区(SVZ)神经干细胞的影响.方法:SD大鼠随机分为正常对照组(6只)、模型组(6只)和电针组(6只).右侧前脑内侧束注射六羟基多巴胺制备PD模型.电针组于造模1周开始高频(100 Hz)电针“合谷”“太冲”穴,每次30 min,每日1次,连续电针21 d.以酪氨酸羟化酶(TH)、抗增殖细胞核抗原(PCNA)以及胶质原纤维酸性蛋白(GFAP)抗体免疫组化阳性分别显示SVZ多巴胺能神经末梢、分裂细胞和神经干细胞.结果:正常对照组右侧纹状体有较强的TH表达,而模型组和电针组的表达均几乎为零;模型组右侧SVZ的PCNA免疫反应阳性细胞数和表达量均显著低于正常对照组(P＜0.01),电针组较模型组均显著增高(P＜0.01);模型组右侧SVZ的GFAP表达水平显著低于正常对照组(P＜0.01),电针组较模型组显著增高(P＜0.05).结论:电针可不通过增加TH表达而逆转PD大鼠损伤侧SVZ的PCNA和GFAP表达减少,提示其改善PD临床症状的可能机制.%Objective To observe the effect of electroacupuncture (EA) on the expression of proliferating cell nuclearrnantigen (PCNA) and glial fibrillary acidic protein (GFAP) in the subventricular zone (SVZ) of Parkinson's disease (PD) rats, sornas to explore its mechanisms underlying improvement of PD. Methods Eighteen SD rats were randomized into normal control9 model and EA groups (6 rats/group). PD model was duplicated by microinjection of 6-hydroxyclopamine (2. 5μg/μL, 6μL) containing d 02% antiscorbic acid into the right medial forebrain bundle region (P; - 4. 0, L: th 8, H: 8. Q). On the 7th day after modeling, EA (100 Hz) was applied to bilateral "Hegu" (LI 4) and "Taichong" (LR 3) for 30 min, once a day for 21 days. The expression levels of tyrosine hydroxylase (TH), GFAP and PCNA in the right SVZ tissue were detected by immunohistochemistry.rnResults TH expression was strong in the normal control group, but no TH expression was found in the model and EA groups. In comparison with the normal control group, the expression levels of PCNA and GFAP proteins and the number of PCNA-IR-positive cells in the right SVZ were decreased significantly in the model group (P<0. 01); while compared with the model group, the expression levels of PCNA and GFAP proteins and the number of PCNA-IR-positive cells in the right SVZ were up-regulated considerably in the EA group (P<0.01,P<0.05). Conclusion EA can up-regulate the expression of PCNA and GFAP proteins in the SVZ in PD rats without changes of TH expression- which may contribute to its effect in improving clinical symptoms of PD.